
New NICE thresholds is good news for ultra-rare disease drugs, says biotech
The National Institute for Health and Care Excellence (NICE), the body that determines the clinical effectiveness and economic value of new medicines, has increased the cost-effectiveness thresholds it applies for drugs that qualify for their Highly Specialised Technology (HST) programme. However, SynaptixBio, the only company licensed to commercialise a treatment for… Read More















